The emphasis on the ability of an anti-MCC DNA vaccine to generate LT-specific CD8+ T cells stems from the fact that MCPyV-specific CD8+ T cells are consistently associated with improved patient outcomes[16,17]. Here, CD8A is linked to Merkel cell skin cancer.